WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Charité University Medicine Berlin

Status and phase: Unknown; Phase 2

Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia

Treatments: Biological: WT1 126-134 peptide

Study type: Interventional

Funder types: Other

Identifiers

NCT00153582

Carreras 04/25f

HaemaCBFWT102

Details and patient eligibility

About

In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin (KLH) as T-helper protein and granulocyte macrophage colony stimulating factor (GM-CSF) 4 times bi-weekly, then monthly.

Full description

In this phase II trial HLA-A2+ patients with active AML without curative treatment option are vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and GM-CSF 4 times bi-weekly, then monthly.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• AML or myelodysplastic syndromes (MDS)
• Partial response (PR) or complete response (CR) or smoldering course without option for allogeneic stem cell transplantation
• HLA-A2+
• WT1-expression in bone marrow

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)